Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM16RIC)

Drug Name
Oprozomib Drug Info
Cross-matching ID
PubChem CID
25067547
ChEBI ID
CHEMBL2103884
CAS Number
CAS 935888-69-0
TTD Drug ID
D02BLD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.70 0.00e+0 44/46 (95.65%) PSMD11;PSMB2;PSMD14;...
Protein processing in endoplasmic reticulum 2.14 0.00e+0 127/171 (74.27%) HSPA1A;HSPA6;DDIT3;...
Collecting duct acid secretion 2.06 2.76e-3 22/27 (81.48%) ATP6V0E1;ATP6V1A;ATP6V1D;...
Parkinson disease 2.00 2.07e-3 176/249 (70.68%) UCHL1;PSMD11;DDIT3;...
Epithelial cell signaling in Helicobacter pylori infect... 1.99 1.66e-3 62/70 (88.57%) ATP6V0E1;ATP6V1A;JUN;...
Spinocerebellar ataxia 1.92 4.14e-3 128/143 (89.51%) PSMD11;PSMB2;PSMD14;...
Amyotrophic lateral sclerosis 1.90 5.91e-3 267/364 (73.35%) SQSTM1;GABARAPL1;PSMD11;...
Lysosome 1.85 1.03e-2 115/128 (89.84%) NPC1;MAN2B1;CLTB;...
Pathways of neurodegeneration 1.77 2.76e-2 354/475 (74.53%) UCHL1;SQSTM1;GABARAPL1;...
Prion disease 1.74 3.06e-2 209/273 (76.56%) HSPA1A;HSPA6;PSMD11;...
Salmonella infection 1.73 3.08e-2 198/249 (79.52%) TUBB2A;FLNC;JUN;...
Vasopressin-regulated water reabsorption 1.72 3.10e-2 40/44 (90.91%) STX4;DYNC1H1;AQP3;...
Synaptic vesicle cycle 1.71 3.18e-2 63/78 (80.77%) DNM1;ATP6V0E1;CLTB;...
Huntington disease 1.68 3.84e-2 233/306 (76.14%) PSMD11;TUBB2A;PSMB2;...
Viral protein interaction with cytokine and cytokine re... 1.68 3.70e-2 84/100 (84%) CXCL14;CXCL2;CXCL8;...
Phagosome 1.67 3.57e-2 118/152 (77.63%) TUBB2A;ATP6V0E1;ATP6V1A;...
Ferroptosis 1.67 3.55e-2 36/41 (87.8%) SLC7A11;GCLM;HMOX1;...
Legionellosis 1.66 3.40e-2 51/57 (89.47%) HSPA1A;HSPA6;CXCL2;...
SNARE interactions in vesicular transport 1.66 3.35e-2 19/33 (57.58%) STX4;STX6;STX18;...
Alzheimer disease 1.63 4.01e-2 279/369 (75.61%) PSMD11;DDIT3;TUBB2A;...
TNF signaling pathway 1.63 3.98e-2 103/112 (91.96%) JUN;CXCL2;TRAF1;...
Rheumatoid arthritis 1.62 4.10e-2 78/93 (83.87%) ATP6V0E1;ATP6V1A;JUN;...
p53 signaling pathway -1.78 3.56e-2 63/73 (86.3%) SIVA1;CCND1;CCNE2;...
DNA replication -1.79 3.96e-2 34/36 (94.44%) MCM5;RPA1;MCM3;...
Valine, leucine and isoleucine degradation -1.90 2.37e-2 42/48 (87.5%) MCCC2;BCAT2;ACAT2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 1.11uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H